Response of relapsed or refractory primary central nervous system lymphoma (PCNSL) to topotecan.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 15159503.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The authors treated 16 immunocompetent patients with refractory or relapsed primary CNS lymphoma with topotecan. Fifteen patients had been pretreated with up to three chemotherapy regimens, three of them additionally with whole brain irradiation (WBI), and one with WBI alone. Four complete remissions and two partial remissions were achieved. Progression-free survival was 20% at 6 months and 13% at 12 months.
Medical subject headings
- Antineoplastic Agents
- Brain Neoplasms
- Lymphoma, Non-Hodgkin
- Salvage Therapy
- Topotecan